William J. Sandborn - 15 Jun 2023 Form 4 Insider Report for Ventyx Biosciences, Inc. (VTYX)

Role
President and Chief Medical Officer
Signature
/s/ Christopher Krueger, as Attorney-in-Fact
Issuer symbol
VTYX
Transactions as of
15 Jun 2023
Net transactions value
-$119,092
Form type
4
Filing time
16 Jun 2023, 21:16:20 UTC
Previous filing
01 Jun 2023
Next filing
27 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VTYX Common Stock Sale $80,730 -2,383 -6.9% $33.88 32,279 15 Jun 2023 By Spouse F1, F2
transaction VTYX Common Stock Sale $38,362 -1,104 -3.4% $34.75 31,175 15 Jun 2023 By Spouse F1, F3
holding VTYX Common Stock 48,389 15 Jun 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person's spouse on December 19, 2022.
F2 Represents the weighted average share price of an aggregate total of 2,383 shares sold in the price range of $33.39 to $34.322. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 Represents the weighted average share price of an aggregate total of 1,104 shares sold in the price range of $34.445 to $34.9565. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Remarks:

President and Chief Medical Officer